These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23292011)

  • 1. [From an illegal drug (so-called non-medically used psychoactive drug) to the designated substance (Shitei-yakubutsu) controlled by the Pharmaceutical Affairs Law in Japan--approach from the laboratory examination to the regulation].
    Satoh K; Kojima T
    Yakugaku Zasshi; 2013; 133(1):1-2. PubMed ID: 23292011
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current situation and issues for analyzing illegal drug products].
    Hasegawa T; Takahashi K; Saijo M; Fukiwake T; Motoki Y
    Yakugaku Zasshi; 2013; 133(1):7-11. PubMed ID: 23292013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analytical data of designated substances (Shitei-Yakubutsu) controlled by the Pharmaceutical Affairs Law in Japan, part I: GC-MS and LC-MS].
    Kikura-Hanajiri R; Kawamura M; Uchiyama N; Ogata J; Kamakura H; Saisho K; Goda Y
    Yakugaku Zasshi; 2008 Jun; 128(6):971-9. PubMed ID: 18520144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shifting from an illegal-drug policy to a psychoactive substance policy.
    van der Linde F
    Soz Praventivmed; 2006; 51(3):128-9. PubMed ID: 17191533
    [No Abstract]   [Full Text] [Related]  

  • 5. [Current and future legislation of illegal drugs in Tokyo].
    Abe T
    Yakugaku Zasshi; 2013; 133(1):3-5. PubMed ID: 23292012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analytical data of designated substances (Shitei-Yakubutsu) controlled by the Pharmaceutical Affairs Law in Japan, part II: Color test and TLC].
    Uchiyama N; Kawamura M; Kamakura H; Kikura-Hanajiri R; Goda Y
    Yakugaku Zasshi; 2008 Jun; 128(6):981-7. PubMed ID: 18520145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug abuse in America: medical and socio-legal dilemmas.
    Garcia SA
    Med Law; 1992; 11(5-6):323-35. PubMed ID: 1484457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of newly distributed designer drugs detected in the products purchased in fiscal year 2008].
    Uchiyama N; Miyazawa N; Kawamura M; Kikura-Hanajiri R; Goda Y
    Yakugaku Zasshi; 2010 Feb; 130(2):263-70. PubMed ID: 20118651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appraisal of the narcotic drugs and psychotropic substances (amendment) act, 2014.
    Mohapatra S; Rath N
    Asian J Psychiatr; 2015 Apr; 14():80-1. PubMed ID: 25838083
    [No Abstract]   [Full Text] [Related]  

  • 10. 'Legal highs' an inappropriate term for 'Novel Psychoactive Drugs' in drug prevention and scientific debate.
    Corazza O; Demetrovics Z; van den Brink W; Schifano F
    Int J Drug Policy; 2013 Jan; 24(1):82-3. PubMed ID: 22883544
    [No Abstract]   [Full Text] [Related]  

  • 11. The 1993 distinguished lecturer in substance abuse.
    Rosenthal MS
    J Subst Abuse Treat; 1994; 11(1):3-7. PubMed ID: 8201631
    [No Abstract]   [Full Text] [Related]  

  • 12. [Analysis of designer drugs detected in the products purchased in fiscal year 2006].
    Uchiyama N; Kikura-Hanajiri R; Kawahara N; Goda Y
    Yakugaku Zasshi; 2008 Oct; 128(10):1499-505. PubMed ID: 18827471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevalence of new designer drugs and their legal status in Japan].
    Kikura-Hanajiri R; Uchiyama N; Kawamura M; Ogata J; Goda Y
    Yakugaku Zasshi; 2013; 133(1):31-40. PubMed ID: 23292017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous and group determination methods for designated substances by HPLC with multi-channel electrochemical detection and their application to real samples.
    Min JZ; Yamashita K; Toyo'oka T; Inagaki S; Higashi T; Kikura-Hanajiri R; Goda Y
    Biomed Chromatogr; 2010 Dec; 24(12):1287-99. PubMed ID: 21077248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Legal and illegal drugs--status, selected problems, trends].
    Katzung W
    Z Arztl Fortbild (Jena); 1992 Jul; 86(14):689-99. PubMed ID: 1529620
    [No Abstract]   [Full Text] [Related]  

  • 16. The law, social control, and drug policy: models, factors, and processes.
    Erickson PG
    Int J Addict; 1993 Oct; 28(12):1155-76. PubMed ID: 8282448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Zealand to establish fit for purpose regulation for new psychoactive substances.
    Sheridan J; Atmore B; Russell B
    Addiction; 2012 Nov; 107(11):1901-2. PubMed ID: 23039748
    [No Abstract]   [Full Text] [Related]  

  • 18. Children and drug law reform.
    Cardoso FH
    Int J Drug Policy; 2012 Jan; 23(1):1-2. PubMed ID: 22071021
    [No Abstract]   [Full Text] [Related]  

  • 19. New psychoactive substances: a public health issue.
    Guirguis A
    Int J Pharm Pract; 2017 Oct; 25(5):323-325. PubMed ID: 28895252
    [No Abstract]   [Full Text] [Related]  

  • 20. The "rainbow" model: an attempt at a global approach to the drug problem.
    Pérez-Gómez A; Jiménez-Suárez S
    Int J Addict; 1993 Apr; 28(5):389-98. PubMed ID: 8478153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.